Pre-solicitationPosted Aug 4, 2026·Responses due Aug 14, 2026

6515--Dry Eye Treatment System

Veterans Affairs · 244-NETWORK CONTRACT OFFICE 4 (36C244)

Stage
Early notice (sources sought, presolicitation or special notice)
NAICS
334510
Value
Not stated
Solicitation
36C24426Q0860
Set-aside
None stated
PSC
6515
Place
Coatesville, USA
Contact
Jeff Mann (jefferson.mann@va.gov)
Loading your pipeline and notes…
CSV Email

Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.

Where this opportunity stands

Every notice posted under solicitation 36C24426Q0860 in this department, oldest first.

Early notice
  • Aug 4, 2026 · this notice
    Pre-solicitation
Solicitation
  • Aug 10, 2026
    Solicitation
    Open
Award
Not yet. Typical award: Aug 19, 2026 to Oct 4, 2026, middle of the range Sep 2, 2026.
Measured from 121 past early notices at Veterans Affairs, Department of with NAICS 334510 that later posted an award (middle half of cases, counted from Aug 4, 2026).

Next steps for this stage

Standard steps for the notice type; not advice about this buyer.

  • Answer the notice: this is when the requirement can still be shaped.
  • Contact the contracting officer named on the notice.
  • Check who won similar work; they are the likely bidders.

What the notice says

In accordance with RFO FAR 5.101, this Presolicitation Notice is issued to inform potential vendors that a solicitation for the Treatment of Dry Eyes will be posted to the government point of entry within the next ten days. All responsible sources may submit a quotation, in accordance with the Request for Quotes (RFQ) requirements, which will be considered by the agency. Vendors are notified that One or more of the items under this acquisition is subject to Free Trade Agreements. Please see RFQ 36C24226Q0710, once posted for further information and submission instructions. STATEMENT OF NEED Co… (show all)

atesville Veterans Affairs Medical Center (VAMC) Optometry Department Treatment Modality for Management of Ocular Surface and Eyelid Disease DESCRIPTION: The Optometry Department of Coatesville VA Medical Center (VAMC) requires a device specifically designed to address ocular surface and eyelid diseases, such as dry eye syndrome, meibomian gland disease, blepharitis, Acne Rosacea, and related skin conditions around the eyes. The required technology must utilize dual frequency monopolar Radio Frequency (RF) and electronic dynamic muscle stimulation (DMS) to deliver heat and muscle stimulation at varying tissue depths. This modality aims to increase blood circulation, enhance meibomian gland function, improve muscle tone, and boost blinking efficiency, thereby providing relief for patients with these conditions. The device must employ monopolar RF technology, which is essential as it reduces the risk of electrical arcing and ensures rapid, uniform heating of deeper eyelid tissues. Dual frequency RF technology is necessary because it does not cause skin depigmentation and is not contraindicated for any patient population. This feature allows for more aggressive management of dry eye in all veterans at Coatesville. Treatments with this technology enhance blood circulation, stimulate collagen production, and support meibomian gland function. Treatments enhance blood circulation, stimulate collagen production, and provide meibomian gland function. Dynamic muscle stimulation is also required for mechanical, non-invasive correction of eyelid muscle tone to restore normal function. Abnormal eyelid function increases the risk of corneal surface irregularities, epithelial breakdown, and permanent vision loss. Dynamic muscle stimulation uses controlled electrical pulses to reactivate and restore resting muscle tone in the orbicularis oculi. These treatments improve blinking efficiency, stabilize the natural tear film, protect the cornea from progressive exposure damage, and reduce the need for daily home care. SCOPE: The contractor shall provide a new FDA approved Monopolar Dual Frequency RF with Electronic Dynamic Muscle Stimulation. The device must be able to treat patients of all skin tones for dry eye syndrome, meibomian gland disease, blepharitis, Acne Rosacea, and conditions affecting the skin around the eyes. All minimum salient characteristics must be met. The Lumenis BE OptiLift System is a Brand Name Product provided for reference comparable salient characteristics only; no brand-name requirement is intended. SALIENT CHARACTERISTICS FDA-approved specifically for ophthalmic and optometric use Clinically validated for treatment of all scope diagnoses Monopolar Application Utilizes dual frequency technology Utilizes electronic dynamic muscle stimulation Multiple RF frequencies capable of tailoring depth and intensity of treatments to specific skin thickness and patient needs Non-pigment dependent system No required anesthesia, topical numbing creams, injections, or eye drops Zero post-procedure downtime Touch screen display Rounded electrode contoured for eyes to maximize patient safety and comfort Automatic treatment presets DELIVERY REQUIREMENTS: Supplier shall perform all required assembly in accordance with the manufacturers instructions. Supplier shall inspect to ensure that the system is clean, has no scratches and that the installation is complete and ready for patient use. The vender will provide on-site training to staff. Vendor shall remove all trash, cartons, debris, and must provide and execute a recycling plan for cartons and cardboard disposal. Vendor shall be responsible for delivery, assembly/installation, and training during normal business hours Monday-Friday 7:30 am to 4:30 pm, excluding any declared Federal Holidays. Scheduling for delivery shall be coordinated at least 7 business days prior to shipment.

Who won similar work

10 award notices on SAM.gov in the last 24 months. Matched by: Same office (244-NETWORK CONTRACT OFFICE 4 (36C244)), same product/service code (PSC) 6515 and NAICS 334510.

Single-winner award sizes (10): middle half $40K to $239K, median $94K; range $19K to $713K.

WinnerAwardsValueLast
RED ONE MEDICAL DEVICES LLC1$713KSep 10, 2025
GEO-MED, LLC1$684KFeb 6, 2025
NIHON KOHDEN AMERICA, LLC1$281KApr 14, 2025
BRAVO, INC. · $CCZ · $121.6B1$112KMar 21, 2025
VETERANS HEALTHCARE SUPPLY SOLUTIONS, INC1$106KMar 20, 2025
WALKER AND MARSHALL MANAGEMENT SERVICES L.L.C.1$82KSep 3, 2026
DEFENSE VENTURE HOLDINGS, LLC1$80KMay 22, 2025
INTELLIGENT HEARING SYSTEMS CORP1$27KJul 8, 2025
E3 DIAGNOSTICS, INC.1$24KSep 11, 2026
BEACON POINT ASSOCIATES LLC1$19KFeb 19, 2025

Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.

Investor context
  • $CCZ reported $121.6B revenue in FY2025. The median single-winner award in these 10 past awards, $94K, is under 0.1% of that. 10-K

One award's total value against one year of revenue; many awards are paid over several years.

Latest awards

Materiality: one award's value as a share of the winner's revenue over the latest 12 months in its SEC filings (or its last fiscal year, as noted when you point at it). Low under 1%, Medium 1 to 5%, High 5% or more. Many awards are paid over several years, so this overstates a single year's share.

Competitive landscape

For the 8 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.

  • 0 of these past winners lobbied Veterans Affairs, Dept of (VA) since 2024 (0 filings)
  • 0 of their lobbyists list a past Veterans Affairs, Dept of (VA) job
  • $131K from their corporate PACs since 2024 to members of House Committee on Appropriations, House Committee on Veterans' Affairs, Senate Committee on Appropriations, Senate Committee on Veterans' Affairs
  • 0 foreign-agent (FARA) registrations
See who and the source records with Pro

Policy around it

Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.

  • 0 bills named on the past winners' lobbying filings
  • 25 rules from the department in the last 12 months
  • 0 executive orders naming the agency in the last 12 months
See who and the source records with Pro

Market

For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.

  • 1 of the past winners are listed companies
  • 0 insider buys and 0 insider sells at them in the last 90 days
See who and the source records with Pro

Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.

Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.